SENTI-202 is under clinical development by Senti Biosciences and currently in Phase I for Blood Cancer. According to GlobalData, Phase I drugs for Blood Cancer have a 68% phase transition success rate ...

The drug is based on an antibody component targeting the CD33 receptor linked to a molecule that breaks down GSPT1, an intracellular protein that is thought to promote the proliferation ...

GT Biopharma, Inc. (NASDAQ:GTBP – Get Free Report) saw a significant increase in short interest in December. As of December 15th, there was short interest totalling 13,700 shares, an increase of 23.4% ...